MedC Biopharma
Cannabis-based Cancer Treatment
Company Overview
Snapshot
Founded in July 2016 by Avi Drori and Guy Drori, MedC Biopharma operates with 11–50 employees. The company has raised $5 million across one funding round. In January 2021, MedC Biopharma partnered with Sana Healthcare to advance its skin oncology platform.
Business overview
MedC Biopharma is a clinical-stage company focused on developing novel treatments for cutaneous T-cell lymphoma, a type of skin cancer, as well as other skin oncology and anxiety-related indications. Its R&D efforts leverage expertise from Professor Hinanit Koltai of the national lab in ARO, Israel, and Professor Emmilia Hodek of Rabin Medical Center, Israel. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Medical Cannabis markets with products like MDC-2060 and DMD-2010.
Strategic signal
In January 2021, MedC Biopharma announced a partnership with Sana Healthcare to advance its skin oncology platform. This collaboration signals a strategic move to accelerate the development and potential commercialization of its pipeline, indicating a focus on expanding its reach and validating its therapeutic approach in the competitive oncology market.
Log in to access full profile ›Company Intelligence Q&A
- What is MedC Biopharma's primary focus?
- MedC Biopharma is a clinical-stage company developing a novel treatment for cutaneous T-cell lymphoma, a type of skin cancer, and has an R&D pipeline that includes additional skin oncology and anxiety-related indications.
- When was MedC Biopharma founded and by whom?
- MedC Biopharma was founded in July 2016 by co-founders Avi Drori and Guy Drori.
- What was a key strategic partnership for MedC Biopharma?
- In January 2021, MedC Biopharma partnered with Sana Healthcare to advance its skin oncology platform.
- What was a significant research publication by MedC Biopharma?
- In June 2020, ARO Volcani Centre, in collaboration with Rabin Medical Centre and MedC Biopharma Corporation, announced the publication of its research in the peer-reviewed scientific journal Oncotarget.
- What was the company's status as of March 2023?
- MedC Biopharma ceased to operate in March 2023.